Phase II Trial of Neoadjuvant Chemotherapy Using Alternating Doublets in Non-Small-Cell Lung Cancer

Martins, Renato; Dienstmann, Rodrigo; Biasi, Paulo de; Dantas, Karina; Santos, Valdelice O.; Toscano, Edson; Roriz, Walter; Zamboni, Mauro; Sousa, Aureliano; Small, I. A.; Moreira, Denise Madeira; Ferreira, Carlos Gil; Zukin, Mauro

doi:10.3816/clc.2007.n.003

Cited by 5 publications

(3 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median 5-year survival was 95 months for stage IB, 78 months for stage IIA and 73 months for stage IIB. 24 Neither study provided information regarding epidemiological data, adjuvant therapy or recurrence in these patients.…”

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Lung cancer in Brazil: epidemiology and treatment challenges

Sá

Coelho

Capelozzi

et al. 2016

LCTT

View full text Add to dashboard Cite

Lung cancer persists throughout the world as a major cause of death. In 2014, data from the Brazilian National Cancer Institute (INCA) estimated 16.400 new cases of lung cancer among men (second most common) and 10.930 new cases among women (fourth most common). These data are consistent for all Brazilian regions and reflect the trends of cancer in the country over the last decade. Brazil is a continental country, the largest in Latin America and fifth in the world, with an estimated population of >200 million. Although the discrepancy in the national income between rich and poor has diminished in the last 2 decades, it is still huge. More than 75% of the Brazilian population do not have private health insurance and rely on the national health care system, where differences in standard of cancer care are evident. It is possible to point out differences from the recommendations of international guidelines in every step of the lung cancer care, from the diagnosis to the treatment of advanced disease. This review aims to describe and recognize these differences as a way to offer a real discussion for future modifications and action points toward delivery of better oncology care in our country.

show abstract

Section: Treatmentmentioning

confidence: 99%

“…In general, the overall survival was better than in those who received chemotherapy in comparison to best support of care, but considerably lower than in those reported in the literature. 23 , 24 , 31 – 33 There are no data regarding maintenance therapy in the Brazilian population.…”

Section: Treatmentmentioning

confidence: 99%

Lung cancer in Brazil: epidemiology and treatment challenges

Sá

Coelho

Capelozzi

et al. 2016

LCTT

View full text Add to dashboard Cite

show abstract

“…In a phase II trial for patients with stage IB to IIIA NSCLC treated with three different chemotherapy schedules, including cisplatin and gemcitabine, a clinical response was seen in 77% of all patients and 67% with N2 disease, resulting in 73% of all participants going on to surgery. 18 Neoadjuvant carboplatin (AUC ϭ 5 on day 1) in combination with gemcitabine (1250 mg/m 2 on days 1 and 8) was tested in 37 patients with stage III disease, resulting in an overall response rate of 51%. Neither CR nor PD was seen in this study.…”

Section: Discussionmentioning

confidence: 99%

Phase II Trial of Neoadjuvant Therapy with Carboplatin, Gemcitabine plus Thalidomide for Stages IIB and III Non-small Cell Lung Cancer

Dudek

Leśniewski-Kmak

Larson³

et al. 2009

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

Lung Cancer in Brazil

Schwartsmann

2012

American Society of Clinical Oncology Educational Book

View full text Add to dashboard Cite

Overview: Cancer is now the second leading cause of death in Brazil (after cardiovascular diseases) and a public health problem, with around 500,000 new cases in 2012. Excluding nonmelanoma skin cancer, lung cancer is the second most incident cancer type in men, with 17,210 expected new cases. In women, it is the fifth most incident cancer, with 10,110 expected new cases. The estimated age-adjusted lung cancer mortality rate is about 13/100,000 for men and 5.4/100,000 for women. Lung cancer rates in men increased until the early 1990s and decreased thereafter, especially in the younger population. In contrast, a steady upward trend was observed for women. The positive effects in men were probably due to the successful anti-tobacco campaign conducted in Brazil over the last decades, which led to a decrease in the adult smoking population, from 32% in the early 1980s to 17% in the 2000s. Although the Brazilian National Cancer Institute is strongly committed to providing excellence in multimodality care to cancer patients, limitations in availability and adequate geographic distribution of specialists and well-equipped cancer centers are evident. Major disparities in patient access to proper staging and state-of-the-art treatment still exist. Considering that World Health Organization (WHO) officials estimate that cancer will become the number one cause of death in most developing countries, including Brazil, in the next decades, it is highly recommended for government authorities to implement firm actions to face this tremendous challenge.

show abstract

Phase II Trial of Neoadjuvant Chemotherapy Using Alternating Doublets in Non-Small-Cell Lung Cancer

Cited by 5 publications

References 32 publications

Lung cancer in Brazil: epidemiology and treatment challenges

Lung cancer in Brazil: epidemiology and treatment challenges

Phase II Trial of Neoadjuvant Therapy with Carboplatin, Gemcitabine plus Thalidomide for Stages IIB and III Non-small Cell Lung Cancer

Lung Cancer in Brazil

Contact Info

Product

Resources

About